6-K ·Filed Sep 11, 2026
Notable filing: 6-K
Actionable Insight ▼ Bearish
The company is burning cash rapidly and explicitly requires additional financing in Q4 2026 to continue operations. Monitor for dilutive equity offerings, potential reverse stock split to maintain Nasdaq listing, or a strategic transaction (merger/asset sale) as the cash runway is extremely tight. The Serenta Phase 3 trial enrollment progress (55% enrolled) is a key binary catalyst but does not offset the immediate financing risk.
Latest settled — T+20d
BDRX ▼ -65.79% at T+20d
SHORT call ✓ call won +65.79% · α vs SPY +68.05% · entry $1.12 → $0.3832
Latest observation: T+29 +41.48% FF3 residual α
T+1d
+18.75%
call -18.75% · α -19.21%
$1.33
settled 6w ago
T+5d
-39.29%
call +39.29% · α +39.40%
$0.6799
settled 6w ago
T+20d
-65.79%
call +65.79% · α +68.05%
$0.3832
settled 18d ago
T+60d
Pending
in 6w
Price Chart
Loading chart...
Executive Summary
No summary provided
Key Facts
- Cash balance at June 30, 2026 was £3.23M, down from £8.53M at December 31, 2025.
- Net cash used in operating activities was £4.61M in H1 2026 vs £3.30M in H1 2025.
- Company states further financing will be required during Q4 2026.
- Material uncertainty related to going concern is explicitly disclosed.
- Market cap is below Nasdaq's proposed $5M minimum market value requirement.
- Post-period end fundraise on July 1, 2026 raised $3.5M in gross proceeds.
- R&D costs increased 75% to £2.92M, driven by the Serenta trial and MTX240 program.
- Revenue was nil for both periods.
- Accumulated deficit reached £157.60M as of June 30, 2026.
- 92 of 168 planned subjects enrolled in the registrational Phase 3 Serenta trial for eRapa in FAP.
Financial Impact
Cash burn of £5.31M in H1 2026; cash runway extended by $3.5M July fundraise but further financing needed in Q4 2026.
cashcash flowgoing concernfinancing
Risk Factors
- Going concern risk: company requires additional financing in Q4 2026 to continue operations.
- Dilution risk: any future financing is likely to be highly dilutive given the micro-cap market cap.
- Nasdaq delisting risk: market cap is below the proposed $5M minimum threshold.
- Clinical trial risk: Serenta Phase 3 trial is still enrolling and results are not expected for an extended period.
- Pre-revenue company with no approved products and no revenue.
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001214659-26-011630 |
| Document: w9102626k.htm | 0001214659-26-011630 |
| Document: 0001214659-26-011630-index-headers.html | 0001214659-26-011630 |
| Document: 0001214659-26-011630-index.html | 0001214659-26-011630 |
| Document: 0001214659-26-011630.txt | 0001214659-26-011630 |
13 reports for BDRX
75% Hit rate @ T+20 Went positive at some point 5 of 6 best @ T+60▲ +76.80%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | 6-K | $0.4849 | awaiting T+20 | — | $3.69 (+660.98%) |
Oct 8, 2026 18d ago | 6-K | $0.4602 | awaiting T+20 | — | $3.69 (+701.83%) |
Oct 1, 2026 26d ago | EFFECT | $0.6326 | awaiting T+20 | — | $3.69 (−483.31%) |
Sep 24, 2026 4w ago | F-1 | $0.6750 $0.4140 | ▲ +38.67% | ▲ +38.25% | $3.69 (−446.67%) |
Sep 15, 2026 5w ago | 6-K | $1.33 $0.3502 | ▼ −73.67% | ▼ −76.65% | $3.69 (+177.44%) |
Sep 11, 2026 6w ago | 6-K | $1.12 $0.3832 | ▲ +65.79% | ▲ +68.05% | $3.69 (−229.46%) |
Aug 4, 2026 12w ago | EFFECT | $11.92 $6.25 | ▲ +47.58% | ▲ +46.35% | $3.69 (+69.04%) |
Jun 30, 2026 16w ago | 6-K | $3.00 $1.45 | ▼ −51.83% | ▼ −49.65% | $3.69 (+23.00%) |
Jun 30, 2026 16w ago | 6-K | $2.91 $1.45 | ▲ +50.34% | ▲ +48.03% | $3.69 (−26.80%) |
Jun 17, 2026 18w ago | 6-K | $3.06 $2.13 | ▼ −30.39% | ▼ −30.93% | $3.69 (+20.59%) |
Showing 10 of 13
US Market Status
Market Closed — Opens in 1h 6m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers